{
  "entities": {
    "activities": {
      "5ccaa52a-43c6-41c6-b38a-65bc2d788ce4": "Bone Marrow Examination",
      "d8ed9914-cc8b-45b4-adef-873c8f316ade": "Bone marrow aspirate for MRD assessment",
      "54b96202-fccc-40a1-89ac-ed417a5ec071": "Bone marrow aspirate to evaluate mechanisms of daratumumab resistance",
      "3646731e-fbb0-4e6e-8124-93036caf8532": "Cytogenetic analysis by conventional karyotype or FISH",
      "51d07791-e57a-4b00-9ff4-9719a925cb6f": "Disease characterization (morphology, and either immunohistochemistry, immunofluorescence, or flow cytometry)",
      "1ea786f6-2e8a-4b93-bc99-71c341968c6a": "Electrocardiogram",
      "c47a726d-5c2e-4716-85b3-ee0126f3f72d": "Evaluate Plasma cell percentage in the bone marrow to confirm CR",
      "69cfbf79-67da-4279-b22b-16326acec971": "Evaluate clonality of plasma cells (by flow cytometry, IHC or IF) in the bone marrow to confirm sCR",
      "afa83cdf-c226-492b-91ed-b409569898ff": "Hepatitis B DNA Testing",
      "f0803ed5-d534-4bed-a4c5-2cf43f2dacef": "Imaging for Lytic Disease",
      "acb27d45-14b2-4616-a41f-138c73a177c6": "Intravenous Infusion",
      "6358a330-bdc4-46d1-bcdf-d2b18b0292a2": "MRD and molecular subtyping",
      "d11343cc-31cc-4f06-9986-3c39f1ba71be": "Physical Examination",
      "f8774f56-39fe-4b55-920a-c9c4246285e3": "Subcutaneous Injection",
      "608c07a3-71ca-4251-81bf-1be6d3bdb25e": "Urine Collection",
      "cd02d0cd-eb47-4a36-9eab-fbface730d9c": "Venipuncture",
      "477fa539-3cbf-46b0-a7a1-220116a4af96": "Vital Signs Monitoring"
    },
    "plannedTimepoints": {},
    "encounters": {
      "fe304a56-0858-4be2-82b0-53f147276f01": "Treatment (Post C1D1)",
      "72af5166-d357-49d3-9720-6e2d195591aa": "Disease Progression Visit",
      "3eb4ccf2-1512-4273-a2aa-8ce8b03a8e23": "Screening (Baseline)",
      "962cb0a1-6487-4ba3-af16-ba2503c7a97f": "Treatment (Suspected CR/sCR)"
    },
    "epochs": {
      "807086e2-be43-4f9d-80b0-f4472429413d": "Screening",
      "3d473be4-c118-404c-b2ed-c403b21b9a86": "During Treatment",
      "1c684cec-ed6f-4bab-b236-da5708188dcc": "Disease Progression"
    },
    "activityGroups": {}
  },
  "cells": {
    "51d07791-e57a-4b00-9ff4-9719a925cb6f|3eb4ccf2-1512-4273-a2aa-8ce8b03a8e23": "both",
    "3646731e-fbb0-4e6e-8124-93036caf8532|3eb4ccf2-1512-4273-a2aa-8ce8b03a8e23": "both",
    "6358a330-bdc4-46d1-bcdf-d2b18b0292a2|3eb4ccf2-1512-4273-a2aa-8ce8b03a8e23": "both",
    "c47a726d-5c2e-4716-85b3-ee0126f3f72d|962cb0a1-6487-4ba3-af16-ba2503c7a97f": "both",
    "69cfbf79-67da-4279-b22b-16326acec971|962cb0a1-6487-4ba3-af16-ba2503c7a97f": "both",
    "d8ed9914-cc8b-45b4-adef-873c8f316ade|962cb0a1-6487-4ba3-af16-ba2503c7a97f": "both",
    "d8ed9914-cc8b-45b4-adef-873c8f316ade|fe304a56-0858-4be2-82b0-53f147276f01": "both",
    "54b96202-fccc-40a1-89ac-ed417a5ec071|72af5166-d357-49d3-9720-6e2d195591aa": "both"
  },
  "cellFootnotes": {
    "69cfbf79-67da-4279-b22b-16326acec971|962cb0a1-6487-4ba3-af16-ba2503c7a97f": [
      "**"
    ],
    "d8ed9914-cc8b-45b4-adef-873c8f316ade|962cb0a1-6487-4ba3-af16-ba2503c7a97f": [
      "*"
    ],
    "d8ed9914-cc8b-45b4-adef-873c8f316ade|fe304a56-0858-4be2-82b0-53f147276f01": [
      "*"
    ]
  },
  "metadata": {
    "model": "gemini-3-flash-preview",
    "extraction_type": "text"
  }
}